Clorox (NYSE: CLX) reported Q2 EPS of $0.98, $0.32 better than the analyst estimate of $0.66. Revenue for the quarter came in at $1.72 billion versus the consensus estimate of $1.66 billion.

GUIDANCE:

Clorox sees FY2023 EPS of $4.05-$4.30, versus the consensus of $4.17.

• Net sales are now expected to be between a 2% decrease to a 1% increase (organic sales from flat to a 3% increase). This compares previously to a 4% decrease to a 2% increase (organic sales from a 3% decrease to a 3% increase).
• Diluted EPS is now expected to be between $3.20 and $3.45, or a 14% to 8% decrease, respectively. This compares previously to between $3.10 and $3.47, or a 17% to 7% decrease, respectively.
• Adjusted EPS is now expected to be between $4.05 and $4.30, or a 1% decrease to a 5% increase, respectively. This compares previously to between $3.85 and $4.22, or a 6% decrease to a 3% increase, respectively. To provide greater visibility into the underlying operating performance of the business, adjusted EPS outlook excludes the long-term strategic investment in digital capabilities and productivity enhancements, estimated to be about 55 cents, as well as the company's streamlined operating model, which is now estimated to increase from 20 cents to approximately 30 cents. While overall expectations for the program remain unchanged, with $75 to $100 million in ongoing annual savings and $75 to $100 million in one-time costs over fiscal years 2023 and 2024, the timing of charges has been adjusted as plans continue to be refined.

For earnings history and earnings-related data on Clorox (CLX) click here.